The latest WHO classification for CNS tumors which will be released in spring 2021 still recognizes glioblastomas with primitive neuronal component, and loss of GFAP expression, MYC/MYCN gene amplification, elevated Ki67 proliferation index and increased cerebrospinal fluid dissemination. Here, MYC is linked to central nervous system neoplasm.